Engrail Therapeutics

Executive Summary

Engrail Therapeutics is a clinical-stage biopharmaceutical company pioneering precision-targeted small molecule therapies for debilitating neurologic, neuropsychiatric, and neurodevelopmental disorders. Founded in 2019 and headquartered in San Diego, the company leverages deep expertise in molecular mechanisms and neurocircuitry to address conditions with high unmet medical need, such as anxiety, depression, and autism spectrum disorders. Engrail's lead program, ENX-101, is a novel positive allosteric modulator of the GABAA receptor subtype with differentiated selectivity, currently in Phase 1 clinical trials. The company aims to improve upon existing treatments by enhancing efficacy while minimizing side effects. With a strong scientific foundation and a focus on validated yet underexploited targets, Engrail is positioned to deliver transformative therapies for patients. Its pipeline includes additional preclinical programs targeting neurodevelopmental and neuropsychiatric indications, leveraging its proprietary platform for rational drug design. As a private company, Engrail has not disclosed funding details but continues to advance its programs toward proof-of-concept.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 top-line data for ENX-101 in anxiety disorder65% success
• Q2 2027IND filing for second program in neurodevelopmental disorder50% success
• Q3 2026Series B or early-stage partnership announcement70% success